Record FY2020 Financial Result Positions Bod for Growth

The Cannabis market has truly exploded in 2020 as Bod Australia record an increase in revenue of 350%.

Bod Australia Limited (ASX: BDA) is pleased to provide this commentary to accompany the release of the audited financial results for the 12 months ending 30 June 2020 (FY2020). Financial summary: Revenue and other income for the period totalled $6.1m, a 350% increase on the prior corresponding period (PCP) (FY2019: $1.34m), and was driven by growth in sales of Bod's hemp-based products in Australia and CBD products in the United Kingdom, and increased prescription volumes being filled for the Company's MediCabilis™ product.

FY2019 & FY2020 Quarterly Revenue Comparison

The loss after income tax was $4,819,140, a 37% decrease on FY2019 (FY2019: $7,623,571). The Company managed to reduce its loss through stringent cost management in areas such as marketing spend, reduced from $2,022,172 to $864,753.

Cash Operating Expenses (FY2019 – FY2020)

Bod expects that revenue will further increase during FY2021, driven by recurring sales orders, new product launches and international expansion. The Company will maintain focus on reducing its operating expenditure, allowing it to pursue a cashflow positive position.

Following the Company's exclusive global agreement with Health & Happiness Group ltd (H&H Group, HKSE: 1112) announced in July 2019, Bod has developed a number of new CBD and hemp products that are being sold under new and existing H&H Group brands. The launch of these new products, coupled with ongoing uptake of the Company's MediCabilis™ product in Australia and UK, has allowed the Company to create a stable and growing revenue base, which will increase during FY2021 and beyond. Bod has several growth initiatives planned for it's CBD and hemp business division, which include product range extensions, new product launches and new market entries into the USA and countries throughout Europe. As well, the Company expects MediCabilis™ prescription sales to grow in Australia and the United Kingdom through new partnerships and as new patients are enrolled in Europe's largest medicinal cannabis registry Project Twenty21 (refer ASX announcement: 8 November 2019).

Bod made excellent progress in FY2020 which is well reflected in these financial results. While top-line growth is our key focus, we have been vigilant managing the cost base, only deploying funds into value-accretive initiatives that will drive future product development and underpin continued revenue growth. This is important as the Company continues to move towards a cashflow positive position CEO Jo Patterson

Mrs Patterson went on to say "We have established a very solid foundation to continue growing at similar rates driven by our diversified revenue streams, exposure to multiple markets, a growing portfolio of products and strong brands, a robust supply chain and excellence in product development. As such, we are exceptionally well-placed for FY021 and beyond. Organic growth is our main focus but we also continue to assess revenue-generating acquisitions that complement existing operations. Bod's strong balance sheet gives the Company a major strategic advantage in the current market."

For the latest news on Bod Australia click here

Disclaimer: Past performance is not an indicator of future performance.

Get the Latest Marijuana News &
Content in your Inbox!

All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors

Mark Page
Mark Page

Mark is a UK born investing enthusiast based in Sydney. He has a keen eye for technical analysis and is paying close attention to the ongoing legalisation of cannabis for the health benefits, opportunities, and emergent industries that will follow.

Leave a Reply

Your email address will not be published. Required fields are marked *